At a glance
Cibinetide research focuses on tissue signaling and small-fiber neuropathy.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source cites neuropathy-related investigations, including symptom measures and nerve-fiber measurements. Those endpoints describe specific study populations rather than a universal nerve-repair effect.[2][3][8]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Ara-290.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 16 mg · 1 source tables
Standard / Gradual Approach (2.0 mL = 8 mg/mL)
| Week | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 2 mg (2,000 mcg) | 25 units (0.25 mL) |
| Weeks 2–8 (or up to 16) | 4 mg (4,000 mcg) | 50 units (0.50 mL) |
Frequency: Inject once daily subcutaneously. Clinical studies used 4 mg/day as the target therapeutic dose, with no additional benefit observed at 8 mg[2][4]. Starting at 2 mg for the first week allows assessment of individual tolerance before reaching the maintenance dose.
Additional schedule context & duration
Concise summary of the once-daily regimen based on clinical trial designs.
- Goal: Support tissue protection, anti-inflammatory signaling, and neuropathic symptom management via IRR activation[2].
- Schedule: Daily subcutaneous injections for 4–8 weeks (clinical trials used 28-day protocols; extension to 8–16 weeks based on individual response).
- Dose Range: 2–4 mg daily; 4 mg is the established target dose.
- Reconstitution: 2.0 mL per 16 mg vial (8 mg/mL) for accurate unit measurements.
- Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated up to 28 days.
Suggested daily titration approach reflecting clinical study parameters.
- Start: 2 mg daily during week 1 to assess tolerance.
- Target: 4 mg daily from week 2 onward[2].
- Frequency: Once per day (subcutaneous).
- Cycle Length: 4–8 weeks standard; may extend to 16 weeks based on individual assessment.
- Timing: Any consistent time daily; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl or roll until fully dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide integrity and potency.
- Lyophilized: Refrigerate at 2–8 °C (35.6–46.4 °F) for up to 2 years; freeze at −20 °C (−4 °F) for extended storage up to 3 years[5].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days and do not freeze the liquid solution[6].
- Allow vials to reach room temperature before opening to minimize condensation; protect from light.
- Discard if discoloration, cloudiness, or particulate matter is observed.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[7][11].
- Clean the vial stopper and injection site with alcohol swabs; allow to dry completely.
- Select a fatty subcutaneous site: lower abdomen (at least 2 inches from navel), outer thigh, or back of upper arm[11].
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12].
- Aspiration is not required for subcutaneous injections; inject slowly and steadily[12].
- Rotate sites systematically with each dose to avoid lipohypertrophy and local tissue changes[7].
- After injection, withdraw the needle and apply gentle pressure with clean gauze; do not rub the site.
Materials & quantity planning
Source materials checklist · 16 mg
Plan based on an 8–16 week daily protocol with gradual titration (2 mg week 1, then 4 mg daily).
-
Peptide Vials (Ara-290, 16 mg each):
- 8 weeks ≈ 14 vials
- 12 weeks ≈ 21 vials
- 16 weeks ≈ 28 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 8 weeks (14 vials): 28 mL → 3 × 10 mL bottles
- 12 weeks (21 vials): 42 mL → 5 × 10 mL bottles
- 16 weeks (28 vials): 56 mL → 6 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 16 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Source document
IUPHAR/BPS Guide to Pharmacology — Cibinetide (ARA-290) ligand profile: structure, receptor binding, and pharmacology (opens in a new tab)www.guidetopharmacology.org
Back to overview ↑ - 05
Public health resource
NCBI Bookshelf — Stability and storage considerations for lyophilized peptide formulations (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Source document
Cleveland Clinic — Subcutaneous injections: where and how to administer at home (opens in a new tab)health.clevelandclinic.org
Back to overview ↑ - 10
Research publication
Peptides Journal (2016) — Zhang W. et al.: ARA 290 relieves pathophysiological pain by targeting TRPV1 channel (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection: patient guide (opens in a new tab)www.hopkinsarthritis.org
Back to overview ↑ - 12
Public health resource
CDC — Vaccine administration: subcutaneous route (angle, site, and technique guidance) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 13
Research publication
PMC Subcutaneous Drug Delivery Review — Pharmacologic considerations of the subcutaneous injection route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑